

Special Issue

An In-Depth Review of Desmoid Tumours

Message from the Guest Editor

Desmoid tumour or desmoid-type fibromatosis is defined as clonal fibroblastic soft tissue neoplasms, characterized by aggressive, infiltrative growth and a tendency toward local recurrence but an inability to metastasize. At present, the majority of management strategies and the order of these is based primarily on expert consensus guidelines and retrospective series. There is a paucity of high-level prospective or randomized evidence; the rarity of desmoid tumours and their heterogeneous behaviour present major challenges in study design. Unfortunately, although it is a growing area of study, there is even less information available on functional outcomes or quality of life for patients afflicted by this disease.

In this Special Issue, we invite original studies and review articles on the molecular pathogenesis and heterogeneous presentation of patients with desmoid tumours, potential predictors of success—such as imaging characteristics—with active surveillance, and therapeutic options (surgery, radiation, hormonal, chemotherapy and minimally invasive or percutaneous approaches) for those who fail active surveillance strategies.

Guest Editor

Dr. Lloyd Mack

Department of Surgery and Oncology, University of Calgary, Calgary, AB, Canada

Deadline for manuscript submissions

15 March 2026



Current Oncology

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 4.9
Indexed in PubMed



mdpi.com/si/203963

Current Oncology
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
currentoncology@mdpi.com

[mdpi.com/journal/
currentoncol](https://mdpi.com/journal/currentoncol)





Current Oncology

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 4.9
Indexed in PubMed



[mdpi.com/journal/
currentcol](https://mdpi.com/journal/currentcol)



About the Journal

Message from the Editor-in-Chief

I am honored and enthusiastic to serve as Editor-in-Chief of *Current Oncology*. Since its establishment in 1994, *Current Oncology* has been playing an important role in the advancement of cancer care by disseminating new knowledge in the cancer care continuum. *Current Oncology* is affiliated with several key cancer societies and provides a global platform to share scientific progress in oncology. We strive for high standards and work together to maintain a rigorous and unbiased peer review process to publish high-quality articles. We have an outstanding editorial team which is committed to the success of *Current Oncology*.

Editor-in-Chief

Prof. Dr. Shahid Ahmed

1. College of Medicine, University of Saskatchewan, Saskatoon, SK S7N5E5, Canada

2. Saskatchewan Cancer Agency, Saskatoon Cancer Center, Saskatoon, SK S7N5H5, Canada

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, and other databases.

Journal Rank:

JCR - Q2 (Oncology)